Sagimet Biosciences Inc.
SGMTDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How SGMT's past catalysts played out
TVB-2640 25 mg (US)
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
TVB-2640
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TVB-2640 25 mg (US) | Phase 2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | - | - |
TVB-2640 | Phase 2 | Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease | - | - |
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
1 drug in this indication
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Sagimet Biosciences Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Sagimet Biosciences Inc.'s (SGMT) pipeline across Phase 2. Its lead program is TVB-2640 25 mg (US) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sagimet Biosciences Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Sagimet Biosciences Inc. (SGMT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SGMT biotech catalysts?→
Add SGMT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sagimet Biosciences Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.